Vancouver Sun (10.09.03) - Monday, October 13, 2003
Canadian Press

People who did not get treatment - although drugs are free - were most likely First Nations, female, poor and/or living in Vancouver's drug-infested Downtown Eastside. An earlier center study said aboriginal injection drug users in Canada's poorest postal code contract HIV at twice the rate of non-aboriginals.

The study called for culturally sensitive interventions to improve access to antiretroviral drugs among HIV-positive aboriginals. The British Columbia Persons With AIDS Society said the report underlines the government's need to increase its ARV budget. "Provincial government inaction in the face of irrefutable evidence is tantamount to criminal negligence," said Glen Bradford, the group's chair.

Epidemiologist Mark Tyndall of the center said no one has been denied state-of-the-art treatment, although the drugs cost up to $14,000 (US$10,607) annually per person. Epidemiologist Dr. Evan Wood, the study's lead author, said he is alarmed that two- thirds of HIV-infected British Columbians discontinue ARV treatment shortly after starting it.

The authors used information from the B.C. Health Ministry's Vital Statistics Agency to evaluate 1,239 HIV-related deaths from January 1995-December 2001.

Woods said he hopes HIV testing and referral at Vancouver's safe injection site will help reduce deaths. He said the center is initiating programs with the Vancouver Coastal Health Authority to improve access to physicians and ARVs in Downtown Eastside.

British Columbia currently spends about $37 million (US$28 million) a year on HIV drug therapy for 3,000 people, including 400 IDUs, according to Brian Hogg, drug treatment manager at the center.

The study, "Prevalence and Correlates of Untreated Human Immunodeficiency Virus Type 1 Infection Among Persons Who Have Died in the Era of Modern Antiretroviral Therapy," is published in the Journal of Infectious Diseases (2003;188(8):1164-1170).
031013
AD032096

Copyright © 2003 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.